These lines of evidence showed the involvement of the ERK/CYP2J2/11,12-EET singling pathway in the pro-glioma effect of M2 microglia/TAMs after JWH133 treatment, thus presenting a promising therapeutic target. The gene discussed is CYP2J2; the disease is glioma.